American Association for Cancer Research (AACR) 2019 – STRO-002 Poster

Apr 11, 2019

American Association for Cancer Research (AACR) 2019

A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-002, An Anti-Folate Alpha (FolRα) Antibody Drug Conjugate, In Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube Or Primary Peritoneal Cancers) And Endometrial Cancers. NCT03748186

Sutro Biopharma, Inc.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.